project id: TCGA-KIRP; case submitter id: TCGA-2Z-A9J2; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.86; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.73; rna integrity number: 8.5; age at index: 71; days to birth: -26134; ethnicity: not hispanic or latino; gender: female; race: white; vital status: Alive; year of birth: 1937; age at diagnosis: 26134; ajcc clinical m: M0; ajcc clinical n: N0; ajcc clinical stage: Stage I; ajcc clinical t: T1a; ajcc pathologic m: MX; ajcc pathologic n: NX; ajcc pathologic stage: Stage I; ajcc pathologic t: T1a; ajcc staging system edition: 6th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 1795.0; icd 10 code: C64.1; last known disease status: not reported; morphology: 8260/3; primary diagnosis: Papillary adenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Kidney, NOS; synchronous malignancy: No; tissue or organ of origin: Kidney, NOS; tumor grade: Not Reported; year of diagnosis: 2008; treatment or therapy: no; alcohol history: Not Reported; cigarettes per day: 1.643835616438356; pack years smoked: 30.0; is ffpe: false; weight: 30.0; composition: Not Reported; days to collection: 2047; days to sample procurement: 0; initial weight: 80.0; portion submitter id: TCGA-2Z-A9J2-01A-11; percent lymphocyte infiltration: 3.0; percent monocyte infiltration: 4.0; percent necrosis: 2.0; percent neutrophil infiltration: 0.0; percent normal cells: 1.0; percent stromal cells: 7.0; percent tumor cells: 90.0; percent tumor nuclei: 92.0;